{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:08:37Z","timestamp":1792505317956,"version":"4.5.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12325-019-01145-8","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T06:03:51Z","timestamp":1574229831000},"page":"364-380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R.","family":"Burmester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Arikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie L.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peigang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Faccin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"1145_CR1","unstructured":"Humira (adalimumab). Summary of product characteristics. Maidenhead: AbbVie; 2018."},{"key":"1145_CR2","unstructured":"Humira (adalimumab). Full prescribing information. North Chicago: AbbVie; 2018."},{"key":"1145_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis. 2013;72:517\u201324.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","volume":"307","author":"K Reich","year":"2015","unstructured":"Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307:875\u201383.","journal-title":"Arch Dermatol Res"},{"key":"1145_CR5","doi-asserted-by":"publisher","first-page":"2e1","DOI":"10.1016\/j.semarthrit.2010.03.003","volume":"40","author":"JR Curtis","year":"2010","unstructured":"Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40:2e1\u201314e1.","journal-title":"Semin Arthritis Rheum"},{"key":"1145_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00296-014-2945-y","volume":"34","author":"T Cobo-Ibanez","year":"2014","unstructured":"Cobo-Ibanez T, Descalzo MA, Loza-Santamaria E, Carmona L, Munoz-Fernandez S. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int. 2014;34:953\u201361.","journal-title":"Rheumatol Int"},{"key":"1145_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6\u00a0months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology. 2011;50:124\u201331.","journal-title":"Rheumatology"},{"key":"1145_CR8","first-page":"2288","volume":"29","author":"A den Broeder","year":"2002","unstructured":"den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29:2288\u201398.","journal-title":"J Rheumatol"},{"key":"1145_CR9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2003.009563","volume":"62","author":"LB van de Putte","year":"2003","unstructured":"van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12\u00a0week, phase II study. Ann Rheum Dis. 2003;62:1168\u201377.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti\u2013tumor necrosis factor \u03b1 monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35\u201345.","journal-title":"Arthritis Rheum"},{"key":"1145_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/03009740410005467","volume":"33","author":"R Rau","year":"2004","unstructured":"Rau R, Simianer S, van Riel PL, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J Rheumatol. 2004;33:145\u201353.","journal-title":"Scand J Rheumatol"},{"key":"1145_CR12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"LB van de Putte","year":"2004","unstructured":"van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508\u201316.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26\u201337.","journal-title":"Arthritis Rheum"},{"key":"1145_CR14","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400\u201311.","journal-title":"Arthritis Rheum"},{"key":"1145_CR15","first-page":"2188","volume":"54","author":"DE Furst","year":"2015","unstructured":"Furst DE, Kavanaugh A, Florentinus S, Kupper H, Karunaratne M, Birbara CA. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatology (Oxford). 2015;54:2188\u201397.","journal-title":"Rheumatology (Oxford)"},{"key":"1145_CR16","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30:2563\u201371.","journal-title":"J Rheumatol"},{"key":"1145_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/ard.2006.066761","volume":"66","author":"GR Burmester","year":"2007","unstructured":"Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66:732\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/art.24106","volume":"59","author":"V Bejarano","year":"2008","unstructured":"Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59:1467\u201374.","journal-title":"Arthritis Rheum"},{"key":"1145_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10067-008-0866-4","volume":"27","author":"AE van der Bijl","year":"2008","unstructured":"van der Bijl AE, Breedveld FC, Antoni CE, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008;27:1021\u20138.","journal-title":"Clin Rheumatol"},{"key":"1145_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0929-6646(09)60071-1","volume":"108","author":"DY Chen","year":"2009","unstructured":"Chen DY, Chou SJ, Hsieh TY, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc. 2009;108:310\u20139.","journal-title":"J Formos Med Assoc"},{"key":"1145_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1471-2474-12-261","volume":"12","author":"B Haraoui","year":"2011","unstructured":"Haraoui B, Cividino A, Stewart J, Guerette B, Keystone EC. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study. BMC Musculoskelet Disord. 2011;12:261.","journal-title":"BMC Musculoskelet Disord"},{"key":"1145_CR22","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/s10165-008-0045-0","volume":"18","author":"N Miyasaka","year":"2008","unstructured":"Miyasaka N, Change Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol. 2008;18:252\u201362.","journal-title":"Mod Rheumatol"},{"key":"1145_CR23","doi-asserted-by":"publisher","first-page":"R24","DOI":"10.1186\/ar4452","volume":"16","author":"GR Burmester","year":"2014","unstructured":"Burmester GR, Matucci-Cerinic M, Mariette X, et al. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5\u00a0years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther. 2014;16:R24.","journal-title":"Arthritis Res Ther"},{"key":"1145_CR24","first-page":"916","volume":"48","author":"F Huang","year":"2009","unstructured":"Huang F, Zhang FC, Bao CD, et al. Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study. Zhonghua Nei Ke Za Zhi. 2009;48:916\u201321.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"1145_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","volume":"72","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72:64\u201371.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/annrheumdis-2012-202433","volume":"73","author":"T Takeuchi","year":"2014","unstructured":"Takeuchi T, Yamanaka H, Ishiguro N, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis. 2014;73:536\u201343.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR27","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3899\/jrheum.151009","volume":"43","author":"GS Kaeley","year":"2016","unstructured":"Kaeley GS, Evangelisto AM, Nishio MJ, et al. Methotrexate dosage reduction upon adalimumab initiation: clinical and ultrasonographic outcomes from the randomized noninferiority MUSICA trial. J Rheumatol. 2016;43:1480\u20139.","journal-title":"J Rheumatol"},{"key":"1145_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/annrheumdis-2013-204769","volume":"74","author":"GR Burmester","year":"2015","unstructured":"Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015;74:1037\u201344.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR29","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.clinthera.2006.10.006","volume":"28","author":"A Kivitz","year":"2006","unstructured":"Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28:1619\u201329.","journal-title":"Clin Ther"},{"key":"1145_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40744-016-0041-3","volume":"3","author":"P Nash","year":"2016","unstructured":"Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40\u00a0mg\/0.4 or 0.8\u00a0mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3:257\u201370.","journal-title":"Rheumatol Ther"},{"key":"1145_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"KB Gordon","year":"2006","unstructured":"Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598\u2013606.","journal-title":"J Am Acad Dermatol"},{"key":"1145_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/247553030713a00101","volume":"13","author":"K Gordon","year":"2007","unstructured":"Gordon K, Blum R, Papp K, et al. Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial. Psoriasis Forum. 2007;13:4\u201311.","journal-title":"Psoriasis Forum"},{"key":"1145_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/247553031117a00201","volume":"17","author":"A Larian","year":"2011","unstructured":"Larian A, Emer JJ, Gordon K, et al. Efficacy and safety of a second adalimumab treatment cycle in psoriasis patients who relapsed after adalimumab discontinuation or dosage reduction: a double-blind, randomized, placebo-controlled trial. Psoriasis Forum. 2011;17:88\u201396.","journal-title":"Psoriasis Forum"},{"key":"1145_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106\u201315.","journal-title":"J Am Acad Dermatol"},{"key":"1145_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","volume":"66","author":"K Gordon","year":"2012","unstructured":"Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3\u00a0years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66:241\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1145_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1346-8138.2009.00748.x","volume":"37","author":"A Asahina","year":"2010","unstructured":"Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II\/III randomized controlled study. J Dermatol. 2010;37:299\u2013310.","journal-title":"J Dermatol"},{"key":"1145_CR37","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/1346-8138.13001","volume":"42","author":"A Asahina","year":"2015","unstructured":"Asahina A, Ohtsuki M, Etoh T, et al. Adalimumab treatment optimization for psoriasis: results of a long-term phase 2\/3 Japanese study. J Dermatol. 2015;42:1042\u201352.","journal-title":"J Dermatol"},{"key":"1145_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","volume":"158","author":"JH Saurat","year":"2008","unstructured":"Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558\u201366.","journal-title":"Br J Dermatol"},{"key":"1145_CR39","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1365-2133.2010.09791.x","volume":"163","author":"D Tha\u00e7i","year":"2010","unstructured":"Tha\u00e7i D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol\/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163:402\u201311.","journal-title":"Br J Dermatol"},{"key":"1145_CR40","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jaad.2010.03.009","volume":"64","author":"BE Strober","year":"2011","unstructured":"Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64:671\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"1145_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/archdermatol.2010.384","volume":"147","author":"C Leonardi","year":"2011","unstructured":"Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147:429\u201336.","journal-title":"Arch Dermatol"},{"key":"1145_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jdv.13746","volume":"31","author":"L Cai","year":"2017","unstructured":"Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31:89\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"90\u20139","key":"1145_CR43","first-page":"e1","volume":"78","author":"BE Elewski","year":"2018","unstructured":"Elewski BE, Okun MM, Papp K, et al. Adalimumab for nail psoriasis: efficacy and safety from the first 26\u00a0weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018;78(90\u20139):e1.","journal-title":"J Am Acad Dermatol"},{"key":"1145_CR44","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04225.x","volume":"26","author":"K Papp","year":"2012","unstructured":"Papp K, Ho V, Teixeira HD, Guerette B, Chen K, Lynde C. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study. J Eur Acad Dermatol Venereol. 2012;26:1007\u201313.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1145_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323\u201333.","journal-title":"Gastroenterology"},{"key":"1145_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"1145_CR47","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56:1232\u20139.","journal-title":"Gut"},{"key":"1145_CR48","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/j.1365-2036.2010.04304.x","volume":"31","author":"R Panaccione","year":"2010","unstructured":"Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2\u00a0years of therapy for Crohn\u2019s disease. Aliment Pharmacol Ther. 2010;31:1296\u2013309.","journal-title":"Aliment Pharmacol Ther"},{"key":"1145_CR49","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829\u201338.","journal-title":"Ann Intern Med"},{"key":"1145_CR50","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","volume":"6","author":"M Watanabe","year":"2012","unstructured":"Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn\u2019s disease. J Crohns Colitis. 2012;6:160\u201373.","journal-title":"J Crohns Colitis"},{"key":"1145_CR51","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.crohns.2014.04.012","volume":"8","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Hibi T, Mostafa NM, et al. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn\u2019s disease. J Crohns Colitis. 2014;8:1407\u201316.","journal-title":"J Crohns Colitis"},{"key":"1145_CR52","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","volume":"142","author":"P Rutgeerts","year":"2012","unstructured":"Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial. Gastroenterology. 2012;142:1102\u201311.","journal-title":"Gastroenterology"},{"key":"1145_CR53","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/j.1365-2036.2010.04466.x","volume":"32","author":"S Lichtiger","year":"2010","unstructured":"Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn\u2019s disease who failed prior infliximab therapy. Aliment Pharmacol Ther. 2010;32:1228\u201339.","journal-title":"Aliment Pharmacol Ther"},{"key":"1145_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ibd.21663","volume":"18","author":"R L\u00f6fberg","year":"2012","unstructured":"L\u00f6fberg R, Louis EV, Reinisch W, et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn\u2019s disease: results from CARE. Inflamm Bowel Dis. 2012;18:1\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"1145_CR55","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1155\/2011\/724813","volume":"25","author":"R Panaccione","year":"2011","unstructured":"Panaccione R, Loftus EV Jr, Binion D, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn\u2019s disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn\u2019s DiseaSe (ACCESS) trial. Can J Gastroenterol. 2011;25:419\u201325.","journal-title":"Can J Gastroenterol"},{"key":"1145_CR56","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779\u201389.","journal-title":"Lancet"},{"key":"1145_CR57","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5217\/ir.2016.14.2.152","volume":"14","author":"KC Wu","year":"2016","unstructured":"Wu KC, Ran ZH, Gao X, et al. Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn\u2019s disease. Intest Res. 2016;14:152\u201363.","journal-title":"Intest Res"},{"key":"1145_CR58","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1002\/art.23044","volume":"56","author":"RG Lambert","year":"2007","unstructured":"Lambert RG, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2007;56:4005\u201314.","journal-title":"Arthritis Rheum"},{"key":"1145_CR59","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.23527","volume":"59","author":"M Dougados","year":"2008","unstructured":"Dougados M, Luo MP, Maksymowych WP, et al. Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. Arthritis Rheum. 2008;59:553\u201360.","journal-title":"Arthritis Rheum"},{"key":"1145_CR60","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696\u2013701.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR61","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3109\/s10165-011-0557-x","volume":"22","author":"S Kobayashi","year":"2012","unstructured":"Kobayashi S, Harigai M, Mozaffarian N, et al. A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis. Mod Rheumatol. 2012;22:589\u201397.","journal-title":"Mod Rheumatol"},{"key":"1145_CR62","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","volume":"73","author":"F Huang","year":"2014","unstructured":"Huang F, Gu J, Zhu P, et al. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis. 2014;73:587\u201394.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR63","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/gut.2010.221127","volume":"60","author":"W Reinisch","year":"2011","unstructured":"Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780\u20137.","journal-title":"Gut"},{"issue":"257\u201365","key":"1145_CR64","first-page":"e1","volume":"142","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(257\u201365):e1\u20133.","journal-title":"Gastroenterology"},{"key":"1145_CR65","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/ajg.2014.242","volume":"109","author":"JF Colombel","year":"2014","unstructured":"Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014;109:1771\u201380.","journal-title":"Am J Gastroenterol"},{"key":"1145_CR66","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","volume":"49","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283\u201394.","journal-title":"J Gastroenterol"},{"key":"1145_CR67","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ecco-jcc\/jjx093","volume":"11","author":"S Travis","year":"2017","unstructured":"Travis S, Feagan BG, Peyrin-Biroulet L, et al. Effect of adalimumab on clinical outcomes and health-related quality of life among patients with ulcerative colitis in a clinical practice setting: results from InspirADA. J Crohns Colitis. 2017;11:1317\u201325.","journal-title":"J Crohns Colitis"},{"key":"1145_CR68","doi-asserted-by":"publisher","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","volume":"157","author":"AB Kimball","year":"2012","unstructured":"Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157:846\u201355.","journal-title":"Ann Intern Med"},{"key":"1145_CR69","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422\u201334.","journal-title":"N Engl J Med"},{"key":"1145_CR70","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279\u201389.","journal-title":"Arthritis Rheum"},{"key":"1145_CR71","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis. 2009;68:702\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR72","first-page":"1040","volume":"34","author":"MC Genovese","year":"2007","unstructured":"Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34:1040\u201350.","journal-title":"J Rheumatol"},{"key":"1145_CR73","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/ar3054","volume":"12","author":"M Rudwaleit","year":"2010","unstructured":"Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12:R117.","journal-title":"Arthritis Res Ther"},{"key":"1145_CR74","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932\u201343.","journal-title":"N Engl J Med"},{"key":"1145_CR75","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183\u201392.","journal-title":"Lancet"},{"key":"1145_CR76","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","volume":"125","author":"EB Suhler","year":"2018","unstructured":"Suhler EB, Adan A, Brezin AP, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125:1075\u201387.","journal-title":"Ophthalmology"},{"key":"1145_CR77","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815\u201322.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR78","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","volume":"392","author":"R Landewe","year":"2018","unstructured":"Landewe R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 2018;392:134\u201344.","journal-title":"Lancet"},{"key":"1145_CR79","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/art.39008","volume":"67","author":"P Mease","year":"2015","unstructured":"Mease P, Sieper J, Van den Bosch F, Rahman P, Karunaratne PM, Pangan AL. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheum. 2015;67:914\u201323.","journal-title":"Arthritis Rheum"},{"key":"1145_CR80","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpeds.2018.05.042","volume":"201","author":"G Horneff","year":"2018","unstructured":"Horneff G, Seyger MMB, Arikan D, et al. Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn\u2019s disease. J Pediatr. 2018;201:166\u201375.","journal-title":"J Pediatr"},{"key":"1145_CR81","volume-title":"Incidence of nonmelanoma skin cancer in the United States","author":"J Scotto","year":"1983","unstructured":"Scotto J, Fears TR, Fraumeni JF, National Cancer Institute (U.S.). Incidence of nonmelanoma skin cancer in the United States. Bethesda: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1983."},{"key":"1145_CR82","volume-title":"Statistical methods in cancer research: volume II\u2014the design and analysis of cohort studies","author":"NE Breslow","year":"1987","unstructured":"Breslow NE, Day NE. Statistical methods in cancer research: volume II\u2014the design and analysis of cohort studies. Lyon: International Agency for Research on Cancer; 1987."},{"key":"1145_CR83","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1136\/ard.2008.102103","volume":"68","author":"GR Burmester","year":"2009","unstructured":"Burmester GR, Mease P, Dijkmans BAC, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009;68:1863\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR84","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","volume":"12","author":"F Atzeni","year":"2012","unstructured":"Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12:225\u20139.","journal-title":"Autoimmun Rev"},{"key":"1145_CR85","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","volume":"137","author":"P Davila-Seijo","year":"2016","unstructured":"Davila-Seijo P, Dauden E, Descalzo MA, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol. 2016;137:313\u201321.","journal-title":"J Invest Dermatol"},{"key":"1145_CR86","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","volume":"7","author":"A Menter","year":"2017","unstructured":"Menter A, Thaci D, Wu JJ, et al. Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther (Heidelb). 2017;7:365\u201381.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1145_CR87","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","volume":"72","author":"SA van Dartel","year":"2013","unstructured":"van Dartel SA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry. Ann Rheum Dis. 2013;72:895\u2013900.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR88","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70:1914\u201320.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR89","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/art.10529","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294\u2013300.","journal-title":"Arthritis Rheum"},{"key":"1145_CR90","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621\u201330.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1145_CR91","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DHPS.S28801","volume":"5","author":"T Ali","year":"2013","unstructured":"Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79\u201399.","journal-title":"Drug Healthc Patient Saf"},{"key":"1145_CR92","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884\u201394.","journal-title":"Arthritis Rheum"},{"key":"1145_CR93","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.rbr.2017.05.003","volume":"57","author":"CL Yonekura","year":"2017","unstructured":"Yonekura CL, Oliveira RDR, Titton DC, et al. Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoracao de Terapias Biologicas\u2014BiobadaBrasil). Rev Bras Reumatol Engl Ed. 2017;57:477\u201383.","journal-title":"Rev Bras Reumatol Engl Ed"},{"key":"1145_CR94","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3899\/jrheum.140102","volume":"91","author":"F Cantini","year":"2014","unstructured":"Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47\u201355.","journal-title":"J Rheumatol Suppl"},{"key":"1145_CR95","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1136\/ard.2010.137422","volume":"70","author":"D Salmon-Ceron","year":"2011","unstructured":"Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70:616\u201323.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR96","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR97","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1080\/14656566.2016.1190336","volume":"17","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Skov L. Management of cardiovascular disease in patients with psoriasis. Expert Opin Pharmacother. 2016;17:1509\u201316.","journal-title":"Expert Opin Pharmacother"},{"key":"1145_CR98","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/art.30654","volume":"64","author":"L Ljung","year":"2012","unstructured":"Ljung L, Simard JF, Jacobsson L, Rantapaa-Dahlqvist S, Askling J, Anti-Rheumatic Therapy in Sweden Study Group. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum. 2012;64:42\u201352.","journal-title":"Arthritis Rheum"},{"key":"1145_CR99","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR100","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaad.2016.07.042","volume":"76","author":"JJ Wu","year":"2017","unstructured":"Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76:81\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"1145_CR101","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1186\/ar2904","volume":"12","author":"A Strangfeld","year":"2010","unstructured":"Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12:R5.","journal-title":"Arthritis Res Ther"},{"key":"1145_CR102","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1002\/art.24941","volume":"60","author":"J Askling","year":"2009","unstructured":"Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009;60:3180\u20139.","journal-title":"Arthritis Rheum"},{"key":"1145_CR103","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/ard.2007.085852","volume":"68","author":"J Askling","year":"2009","unstructured":"Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009;68:648\u201353.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR104","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/art.27402","volume":"62","author":"K Hellgren","year":"2010","unstructured":"Hellgren K, Smedby KE, Feltelius N, Baecklund E, Askling J. Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis. Arthritis Rheum. 2010;62:1252\u20138.","journal-title":"Arthritis Rheum"},{"key":"1145_CR105","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","volume":"8","author":"MD Long","year":"2010","unstructured":"Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268\u201374.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1145_CR106","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/jnci\/90.17.1278","volume":"90","author":"RS Stern","year":"1998","unstructured":"Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst. 1998;90:1278\u201384.","journal-title":"J Natl Cancer Inst"},{"key":"1145_CR107","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692\u2013701.","journal-title":"Arthritis Rheum"},{"key":"1145_CR108","first-page":"2130","volume":"32","author":"EF Chakravarty","year":"2005","unstructured":"Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130\u20135.","journal-title":"J Rheumatol"},{"key":"1145_CR109","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","volume":"7","author":"CA Siegel","year":"2009","unstructured":"Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874\u201381.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1145_CR110","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56:2886\u201395.","journal-title":"Arthritis Rheum"},{"key":"1145_CR111","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer LK, Regierer AC, Mariette X, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017;76:2025\u201330.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR112","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/art.38339","volume":"66","author":"K Hellgren","year":"2014","unstructured":"Hellgren K, Smedby KE, Backlin C, et al. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden. Arthritis Rheumatol. 2014;66:1282\u201390.","journal-title":"Arthritis Rheumatol"},{"key":"1145_CR113","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","volume":"108","author":"N Sattar","year":"2003","unstructured":"Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how \u201chigh-grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957\u201363.","journal-title":"Circulation"},{"key":"1145_CR114","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331.","journal-title":"N Engl J Med"},{"key":"1145_CR115","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Landewe R, Genovese MC, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:414\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1145_CR116","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","volume":"12","author":"C Leonardi","year":"2011","unstructured":"Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12:321\u201337.","journal-title":"Am J Clin Dermatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01145-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-019-01145-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01145-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T17:37:03Z","timestamp":1650389823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-019-01145-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01145-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"8 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}